Basophils and eosinophils in allergic rhinitis

Abstract

and HLA-DR positivity in the dermis. Arthritis Rheum 1988;31:672-7. 60. Seibold JR, Giorno RC, Claman HN. Dermal mast cell degranulation in systemic sclerosis. Arthritis Rheum 1990; 33:1702-9. 61. Chanez P, Lacoste J-Y, Guillot B, et al. Mast cells' contribution to the fibrosing alveolitis of the scleroderma lung. Am Rev Resp Dis 1993;147:1497-502. 62. de Paulis A, Valentini G, Spadaro G, Lupoli S, Tirri G, Marone G. Human basophil releasability. VIII. Increased basophil releasability in patients with scleroderma. Arthritis Rheum 1991;34:1289-96. 63. Kaufman LD, Gruber BL, Marchese M J, Seibold JR. Anti-IgE autoantibodies in systemic sclerosis (scleroderma). Ann Rheum Dis 1989;48;201-5. 64. Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol 1992;52:333-423. 65. Columbo M, Horowitz EM, Botana LM, et al. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cell and peripheral blood basophils. J Immunol 1992;149:599-608. 66. de Paulis A, Ciccarelli A, Cirillo R, de Crescenzo G, Columbo M, Marone G. Modulation of human lung mast cell function by the c-kit receptor ligand. Int Arch Allergy Immunol 1992;99:326-9. 67. MacGlashan DW Jr, Hubbard WC. IL-3 alters free arachidonic acid generation in C5a-stimulated human basophils. J Immunol 1993;151:6358-69. 68. Cirillo R, Triggiani M, Siri L, et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 1990;144: 3891-7. 69. de Paulis A, Ciccarelli A, Cirillo R, de Crescenzo G, Columbo M, Marone G. Cytokine-induced modulation of human Fc,RI + inflammatory cells. In: Romagnani S, Mosmann TR, Abbas AK, eds. New advances on cytokines. New York: Raven Press, 1992:367-86. 70. Merget RD, Maurer AB, Koch U, et al. Histamine release from basophils after in vivo application of recombinant human interleukin-3 in man. Int Arch Allergy Appl Immunol 1990;92:366-74. 71. White MV, Igarashi Y, Emmery BE, Lotze MT, Kaliner MA. Effects of in vivo administration of interleukin-2 (IL-2) and IL-4, alone and in combination, on ex vivo human basophil histamine release. Blood 1992;76:1491-5.